Compare Honest Company Inc (HNST) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Incyte Corporation — how do they compare? Honest Company Inc trades at $5.07 (market cap $533.20M), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 42.9× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Incyte Corporation for 33 Days on average.
| HNST | INCY | |
|---|---|---|
Market Cap | $533.20M | $22.85B |
Volume | 1,990,155 | 1,927,029 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $129.93 |
52-Week Low | $2.10 | $83.80 |
Typical Hold Time | 39 Days | 33 Days |
Enterprise Value | $436.81M | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, up 2.84% today, but remains in a bearish technical trend. The company shows mixed fundamentals with declining revenue to $371.32M in 2025 and a net loss of -$15.69M, though Q2 2026 earnings beat expectations. Analyst sentiment is cautious with a $5.30 consensus target, while institutional buying from BlackRock and Deutsche Bank provides some support.
The outlook remains challenging with persistent profitability issues and competitive pressures. While strategic exits show early promise and cash flow improved to $14.15M in 2025, investors face risks from margin compression and uncertain growth trajectory. The stock trades at premium valuations despite negative returns, requiring careful risk assessment.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
